Review Article
Glomerular Disease in Patients with Infectious Processes Developing Antineutrophil Cytoplasmic Antibodies
Table 7
Treatment and outcomes of 50 patients with development of ANCA positivity and glomerulonephritis during the course of infectious episodes.
| | Treatment method | (%) | Outcome | (%) |
| | Pauci-immune glomerulonephritis1 | 23 | | | | Antibiotics | 10 (43) | Improvement/recovery | 17 (74) | | Corticosteroids | 22 (96) | Death | 3 (13) | | Cyclophosphamide | 17 (74) | Not reported | 3 (13) | | Plasma exchange | 2 (9) | | | | Interferon-a2b | 1 (4) | | | | Aortic valve replacement | 1 (4) | | | | Postinfectious glomerulonephritis1 | 19 | | | | Antibiotics | 17 (89) | Improvement/recovery | 14 (74) | | Corticosteroids | 11 (58) | Dialysis | 3 (16) | | Cardiac valve replacement | 3 (16) | Death | 5 (26) | | Atrioventricular shunt removal | 3 (16) | | | | Ventricular septal defect repair | 1 (5) | | | | Intravenous immunoglobulins | 1 (5) | | | | Plasma exchange | 1 (5) | | | | Interferon-a2b | 1 (5) | | | | Cyclophosphamide | 1 (5) | | | | Other types of renal disease | 9 | — | — | | Antibiotics | 8 (89) | Improvement/recovery | 6 (67) | | Corticosteroids | 2 (22) | Chronic renal failure | 2 (22) | | Aortic valve replacement | 1 (11) | Death | 1 (11) | | Cyclophosphamide | 1 (11) | | |
|
|
1Including two patients with dual glomerulopathy [120, (a) and (b)].
|
